Prof Jason R Andrews MD, Salome Charalambous PhD, Prof Gavin Churchyard PhD, Prof Frank Cobelens PhD, Carlos Fernández-Escobar MD, Mike Frick MSc, Prof Willem Hanekom MBChB, Prof Mark Hatherill MD, Prof Philip C Hill MD, Surabhi Pandey PhD, Prof Molebogeng X Rangaka PhD, Prof Richard G White PhD, Everton F Lemos PhD, Alessandra Moura da Silva, Julio Croda PhD, Alberto L Garcia-Basteiro PhD
{"title":"The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research?","authors":"Prof Jason R Andrews MD, Salome Charalambous PhD, Prof Gavin Churchyard PhD, Prof Frank Cobelens PhD, Carlos Fernández-Escobar MD, Mike Frick MSc, Prof Willem Hanekom MBChB, Prof Mark Hatherill MD, Prof Philip C Hill MD, Surabhi Pandey PhD, Prof Molebogeng X Rangaka PhD, Prof Richard G White PhD, Everton F Lemos PhD, Alessandra Moura da Silva, Julio Croda PhD, Alberto L Garcia-Basteiro PhD","doi":"10.1016/s1473-3099(25)00305-6","DOIUrl":null,"url":null,"abstract":"People deprived of liberty are among the populations experiencing the highest rates of tuberculosis. Prisons typically create ideal conditions for <ce:italic>Mycobacterium tuberculosis</ce:italic> transmission, including overcrowding and prolonged exposure in poorly ventilated environments, and often have populations at high risk of developing disease. The development of a novel, effective tuberculosis vaccine to prevent adult pulmonary tuberculosis is considered a crucial objective for improving tuberculosis control and, ultimately, elimination. Currently, there are over a dozen vaccines in clinical development, although none of the ongoing or planned trials include people deprived of liberty. Several factors contribute to this exclusion, including historical ethical violations in medical research involving this population, as well as concerns regarding coercion and exploitation. In this Personal View, we contend that these concerns need to be weighed against people deprived of liberty's right to participate in scientific progress and the importance of respecting their autonomy to be part of medical research. We address the key risks associated with conducting tuberculosis vaccine trials involving people deprived of liberty, propose mitigation strategies, and discuss important scientific considerations related to efficacy trials in this context.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"634 1","pages":""},"PeriodicalIF":36.4000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s1473-3099(25)00305-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
People deprived of liberty are among the populations experiencing the highest rates of tuberculosis. Prisons typically create ideal conditions for Mycobacterium tuberculosis transmission, including overcrowding and prolonged exposure in poorly ventilated environments, and often have populations at high risk of developing disease. The development of a novel, effective tuberculosis vaccine to prevent adult pulmonary tuberculosis is considered a crucial objective for improving tuberculosis control and, ultimately, elimination. Currently, there are over a dozen vaccines in clinical development, although none of the ongoing or planned trials include people deprived of liberty. Several factors contribute to this exclusion, including historical ethical violations in medical research involving this population, as well as concerns regarding coercion and exploitation. In this Personal View, we contend that these concerns need to be weighed against people deprived of liberty's right to participate in scientific progress and the importance of respecting their autonomy to be part of medical research. We address the key risks associated with conducting tuberculosis vaccine trials involving people deprived of liberty, propose mitigation strategies, and discuss important scientific considerations related to efficacy trials in this context.
期刊介绍:
The Lancet Infectious Diseases was launched in August, 2001, and is a lively monthly journal of original research, review, opinion, and news covering international issues relevant to clinical infectious diseases specialists worldwide.The infectious diseases journal aims to be a world-leading publication, featuring original research that advocates change or sheds light on clinical practices related to infectious diseases. The journal prioritizes articles with the potential to impact clinical practice or influence perspectives. Content covers a wide range of topics, including anti-infective therapy and immunization, bacterial, viral, fungal, and parasitic infections, emerging infectious diseases, HIV/AIDS, malaria, tuberculosis, mycobacterial infections, infection control, infectious diseases epidemiology, neglected tropical diseases, and travel medicine. Informative reviews on any subject linked to infectious diseases and human health are also welcomed.